Literature DB >> 16864709

Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution syndrome.

Rasa Verkauskiene1, Catherine Dollfus, Martine Levine, Albert Faye, Samia Deghmoun, Muriel Houang, Didier Chevenne, Jean-Louis Bresson, Stéphane Blanche, Claire Lévy-Marchal.   

Abstract

Human immunodeficiency virus (HIV)-related lipodystrophy is characterized by adipose tissue redistribution, dyslipidemia, and insulin resistance. We hypothesized that fat redistribution and metabolic abnormalities in HIV-infected children are related to alterations in endocrine function of adipose tissue. A multicenter study was conducted in 130 HIV-infected children. Lipodystrophy definition was based on the central to peripheral skinfold ratio. Fasting adiponectin, leptin, insulin concentrations, glycemia, and lipid profile were measured in all children. Fat redistribution syndrome was apparent in 32 children: 14 with atrophic (LPDA) and 18 with hypertrophic lipodystrophy (LPDH). Mean serum adiponectin levels were significantly decreased in LPDA and LPDH groups compared with the group with no lipodystrophy (LPD-). Fasting insulin concentration was significantly higher in LPDA and LPDH groups versus LPD-. Mean serum leptin concentration was significantly increased only in LPDH compared with LPDA and LPD- groups. Triglyceride levels were significantly increased and high-density lipoprotein (HDL)-cholesterol concentration decreased in the LPDA versus LPD- group. Controlling for puberty stage, gender, percentage of total fat mass, serum lipids, HIV treatment, and disease severity, adiponectin was significantly and inversely associated with central obesity and insulin/glucose ratio. Fat redistribution had no significant effect on leptin concentration, which was directly related to the percentage of body fat, female gender, and insulin/glucose ratio. In conclusion, HIV-infected children with symptoms of fat redistribution have decreased levels of adiponectin, associated with insulin resistance and dyslipidemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16864709     DOI: 10.1203/01.pdr.0000228335.64894.26

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

1.  Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy.

Authors:  C J Chantry; J S Cervia; M D Hughes; C Alvero; J Hodge; P Borum; J Moye
Journal:  HIV Med       Date:  2010-03-21       Impact factor: 3.180

Review 2.  Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients.

Authors:  Roy J Kim; Richard M Rutstein
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

Review 3.  Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.

Authors:  Absalon D Gutierrez; Ashok Balasubramanyam
Journal:  Endocrine       Date:  2011-12-02       Impact factor: 3.633

4.  Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection.

Authors:  Rick B Meeker; Winona Poulton; Silva Markovic-Plese; Colin Hall; Kevin Robertson
Journal:  J Neurovirol       Date:  2011-05-10       Impact factor: 2.643

5.  Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood.

Authors:  David Dimock; Vijaya Thomas; Anna Cushing; Julia B Purdy; Carol Worrell; Jeffrey B Kopp; Rohan Hazra; Colleen Hadigan
Journal:  Metabolism       Date:  2010-10-13       Impact factor: 8.694

6.  Virtual support for paediatric HIV treatment decision making.

Authors:  Kirsty Le Doare; N E Mackie; S Kaye; A Bamford; S Walters; C Foster
Journal:  Arch Dis Child       Date:  2014-12-30       Impact factor: 3.791

7.  Effects of HIV infection on the metabolic and hormonal status of children with severe acute malnutrition.

Authors:  Aaloke Mody; Sarah Bartz; Christoph P Hornik; Tonny Kiyimba; James Bain; Michael Muehlbauer; Elizabeth Kiboneka; Robert Stevens; John V St Peter; Christopher B Newgard; John Bartlett; Michael Freemark
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.